Beyond Air has submitted a supplement application to the U.S. Food and Drug Administration (FDA) for its LungFit PH 2, a second-generation device for administering nitric oxide (NO) to treat persistent pulmonary hypertension of the newborn (PPHN). LungFit PH 2 is a smaller, lightweight, transport-ready version of the…
Low-dose metformin, a medication for type 2 diabetes, delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of pulmonary arterial hypertension (PAH) in rats, a study reports. “Administration of [metformin] nanocapsules is a safe and innovative therapeutic approach for PAH,” the researchers wrote. “This method could improve…
Treatment with Opsynvi (macitentan and tadalafil) as a single-tablet combination therapy for people with pulmonary arterial hypertension (PAH) is highly valued by patients and endorsed by clinicians, according to interviews conducted during the Phase 3 A DUE trial. All patients interviewed said that a single, once-a-day pill to…
A higher diameter ratio on CT scans between the right ventricle and left ventricle, which are the heart’s lower chambers, independently predicts major adverse cardiovascular events in people with pulmonary hypertension (PH), a study reports. “In our study, the [right ventricle/left ventricle] ratio not only well reflected PH severity,…
Boosting the production of a protein called myotubularin-related protein 7 (MTMR7) reversed signs of pulmonary arterial hypertension (PAH) in a mouse model of the disease, a study shows. MTMR7 suppresses the excess growth and migration of cells lining the arteries, which contribute to the narrowing of these blood vessels…
Inhibiting an enzyme known as Aurora kinase B (AURKB) significantly improves multiple measures of blood flow in rat models of pulmonary arterial hypertension (PAH), a study suggests. AURKB blockade worked by suppressing the excessive growth of blood vessel muscle cells, which contributes to the narrowing of pulmonary arteries that…
Cereno Scientific‘s investigational oral therapy CS1 improves right heart function in people with pulmonary arterial hypertension (PAH), according to new data from a Phase 2a clinical trial. Three months of treatment also boosted quality of life, while symptoms associated with heart failure and the risk of clinical worsening…
Lungpacer Medical’s AeroNova diaphragm neurostimulation system significantly reduced pulmonary hypertension (PH) among critically ill patients with lung failure while they were on mechanical ventilation, according to data from the STIMULUS trial. The device, which electrically stimulates nerves to activate the diaphragm muscles in synchrony with mechanical ventilation, also…
Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary arterial hypertension (PAH) in rats, a study reports. “This study offers a fresh outlook upon understanding the role of macrophages in PAH and provides experimental evidence in developing targeted therapeutic strategies,” the researchers…
Anoikis, a form of programmed cell death, is involved in the development of chronic thromboembolic pulmonary hypertension (CTEPH), according to a genetic analysis study. Researchers identified two anoikis-related genes associated with CTEPH — PLAUR and HMOX1 — which may serve as diagnostic biomarkers or as…
Men with pulmonary arterial hypertension (PAH) have a larger right heart size and worse survival rates than women, independent of body size and functional status, a study reports. Moreover, sex-specific mortality risk thresholds, with higher risk indicated by a larger area of the right pulmonary artery, as measured by…
The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This regimen is “well-justified based on the totality of the observed safety and efficacy data from Phase 2 and Phase 3…
Get regular updates to your inbox.